miR-122 – A key factor and therapeutic target in liver disease
Open accessThe DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Abstract
Being the largest internal organ of the human body with the unique ability of self-regeneration, the liver is involved in a wide variety of vital functions that require highly orchestrated and controlled biochemical processes. Increasing evidence suggests that microRNAs (miRNAs) are essential for the regulation of liver development, regeneration and metabolic functions. Hence, alterations in intrahepatic miRNA networks have been associated with liver disease including hepatitis, steatosis, cirrhosis and hepatocellular carcinoma (HCC). miR-122 is the most frequent miRNA in the adult liver, and a central player in liver biology and disease. Furthermore, miR-122 has been shown to be an essential host factor for hepatitis C virus (HCV) infection and an antiviral target, complementary to the standard of care using direct-acting antivirals or interferon-based treatment. This review summarizes our current understanding of the key role of miR-122 in liver physiology and disease, highlighting its role in HCC and viral hepatitis. We also discuss the perspectives of miRNA-based therapeutic approaches for viral hepatitis and liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
miR-122 Regulates Tumorigenesis in Hepatocellular Carcinoma by Targeting AKT3
Nassirpour, R., Mehta, P. P., & Yin, M.-J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079655 · Cited by 101
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Most mammalian mRNAs are conserved targets of microRNAs
Friedman, R. C., Farh, K. K.-H., Burge, C. B., & Bartel, D. P. (2009) · Genome Research · doi:10.1101/gr.082701.108 · Cited by 8,462
The widespread regulation of microRNA biogenesis, function and decay
Krol, J., Loedige, I., & Filipowicz, W. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2843 · Cited by 4,672 · cited 1×
“These specific expression patterns are controlled by both transcriptional and post-transcriptional regulatory systems that may target different steps of miRNA biogenesis and turnover (for a detailed discussion, see [12]).”
BackgroundSilencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949 · cited 4×
“both mice and non-human primates [34–36].”
BackgroundInfluentialmiRBase: integrating microRNA annotation and deep-sequencing data
Kozomara, A., & Griffiths-Jones, S. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1027 · Cited by 3,634 · cited 1×
“miRNAs have been identified in 206 organisms, ranging from microbes to animal species, including humans, where 2000 miRNAs are currently reported by the official miRNA repository miRBase (release 20, [3]).”
BackgroundA Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing
Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N., Aravin, A., Pfeffer, S., Rice, A., Kamphorst, A. O., Landthaler, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.040 · Cited by 3,626 · cited 1×
“Given their involvement in regulating cell homeostasis and functions, miRNA expression is tightly controlled in a temporally restrained and tissue-specific manner [10,11].”
BackgroundSelf-citationIdentification of tissue-specific microRNAs from mouse
Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00809-6 · Cited by 3,355 · cited 2×
“miR-122 has a liver-enriched expression and is one of the most abundant miRNAs in the liver, accounting for about 70% and 52% of the whole hepatic miRNome in adult mouse and human, respectively [20–22].”
BackgroundAn RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells
Hammond, S. M., Bernstein, E., Beach, D., & Hannon, G. J. (2000) · Nature · doi:10.1038/35005107 · Cited by 3,003
Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA
Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., & Sarnow, P. (2005) · Science · doi:10.1126/science.1113329 · Cited by 2,521
Cited by
Regulation of microRNA function in animals
Gebert, L. F. R., & MacRae, I. J. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0045-7 · Cited by 2,284
Extracellular miRNAs: From Biomarkers to Mediators of Physiology and Disease
Mori, M. A., Ludwig, R. G., Garcia-Martin, R., Brandão, B. B., & Kahn, C. R. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.011 · Cited by 961
Lou, G., Song, X., Yang, F., Wu, S., Wang, J., Chen, Z., & Liu, Y. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0220-7 · Cited by 651
MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases
Wang, X., He, Y., Mackowiak, B., & Gao, B. (2021) · Gut · doi:10.1136/gutjnl-2020-322526 · Cited by 495
Circulating MicroRNAs as Biomarkers for Sepsis
Benz, F., Roy, S., Trautwein, C., Roderburg, C., & Luedde, T. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17010078 · Cited by 257
Emerging roles of circRNA in formation and progression of cancer
Yin, Y., Long, J., He, Q., Li, Y., Liao, Y., He, P., & Zhu, W. (2019) · Journal of Cancer · doi:10.7150/jca.30828 · Cited by 219
“Among them, miR-122 is one of the most abundant miRNAs in the liver and plays a central role in the HCV life cycle [44].”
BackgroundLou, G., Yang, Y., Liu, F., Ye, B., Chen, Z., Zheng, M., & Liu, Y. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13208 · Cited by 205
“Bing the most abundant miRNA in a normal liver, miR-122 is reduced in advanced liver diseases, such as cirrhosis and hepatocellular carcinoma [8, 9].”
BackgroundMicroRNAs in placental health and disease
Mouillet, J.-F., Ouyang, Y., Coyne, C. B., & Sadovsky, Y. (2015) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.05.057 · Cited by 195
Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives
Liu, S.-Y., Tsai, I.-T., & Hsu, Y.-C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105170 · Cited by 183
Ameling, S., Kacprowski, T., Chilukoti, R. K., Malsch, C., Liebscher, V., Suhre, K., Pietzner, M., Friedrich, N., Homuth, G., Hammer, E., et al. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0136-7 · Cited by 181
Hepatocyte polyploidization and its association with pathophysiological processes
Wang, M.-J., Chen, F., Lau, J. T. Y., & Hu, Y.-P. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.167 · Cited by 172
Jin, X., Feng, C.-Y., Xiang, Z., Chen, Y.-P., & Li, Y.-M. (2016) · Oncotarget · doi:10.18632/oncotarget.12186 · Cited by 166
Baran-Gale, J., Kurtz, C. L., Erdos, M. R., Sison, C., Young, A., Fannin, E. E., Chines, P. S., & Sethupathy, P. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00352 · Cited by 120
“Included in this list is miR-122, which has a critical role in liver biology and disease (Tsai et al., 2012; Bandiera et al., 2015).”
BackgroundTakeishi, K., Collin de l’Hortet, A., Wang, Y., Handa, K., Guzman-Lepe, J., Matsubara, K., Morita, K., Jang, S., Haep, N., Florentino, R. M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107711 · Cited by 118
“mRNA analysis of HGF and DMSO-treated cells (stage 3) showed upregulation of liver-enriched transcription factors FOXA1, FOXA2, HNF4α, HNF1α, CCAAT enhancer binding protein alpha (CEBPα), peroxisome proliferator-activated receptor alpha (PPARα), liver X receptor (LXR), and retinoid X receptor (RXR; Figure 1C), and liv…”
Background
Metadata
- Authors
- Bandiera, S., Pfeffer, S., Baumert, T. F., & Zeisel, M. B.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 62
- Issue
- 2
- Pages
- 448-457
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2054984901
- Cited by
- 629
- References
- 122
- FWCI
- 12.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.